Drug intelligence / Profile preview

Pediatric pulmonary fever cough and asthma granules

Development stage: Unknown
Lead developer: Hainan Huluwa Pharmaceutical Group
Administration: Oral

Overview

Pediatric pulmonary fever cough and asthma granules (Xiao'er Feire Kechuan Keli) is a traditional Chinese medicine (TCM) formulation indicated for the treatment of pediatric acute bronchitis, common cold, asthmatic bronchitis, and bronchopneumonia characterized by phlegm-heat obstructing the lung. It is composed of multiple herbal ingredients known for their properties in clearing heat, detoxifying, relieving cough, resolving phlegm, and calming asthma. The drug is administered orally as granules. It is an approved pharmaceutical product in China.

Brand names: HuluwaSunflower
Other names: Pulmonary Fever Cough And AsthmaXiao'er Feire Kechuan Keli

Beyond the preview

Go deeper on Pediatric pulmonary fever cough and asthma granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pediatric pulmonary fever cough and asthma granules.

Explore the full profile